Microbial Proteins in Stomach Biopsies Associated with Gastritis, Ulcer, and Gastric Cancer

Shahid Aziz 1,2,3,*, Faisal Rasheed 1, Tayyab Saeed Akhter 4, Rabaab Zahra 2 and Simone König 3

1 Patients Diagnostic Lab, Isotope Application Division, Pakistan Institute of Nuclear Science and Technology (PINSTECH), Islamabad 44000, Pakistan
2 Department of Microbiology, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan
3 IZKF Core Unit Proteomics, University of Münster, 48149 Münster, Germany
4 The Centre for Liver and Digestive Diseases, Holy Family Hospital, Rawalpindi 46300, Pakistan
* Correspondence: saziz@bs.qau.edu.pk or sazizhpl@gmail.com

Abstract: (1) Background: Gastric cancer (GC) is the fourth leading cause of cancer-related deaths worldwide. *Helicobacter pylori* infection is a major risk factor, but other microbial species may also be involved. In the context of an earlier proteomics study of serum and biopsies of patients with gastroduodenal diseases, we explored here a simplified microbiome in these biopsies (*H. pylori*, *Acinetobacter baumannii*, *Escherichia coli*, *Fusobacterium nucleatum*, *Bacteroides fragilis*) on the protein level. (2) Methods: A cohort of 75 patients was divided into groups with respect to the findings of the normal gastric mucosa (NGM) and gastroduodenal disorders such as gastritis, ulcer, and gastric cancer (GC). The *H. pylori* infection status was determined. The protein expression analysis of the biopsy samples was carried out using high-definition mass spectrometry of the tryptic digest (label-free data-independent quantification and statistical analysis). (3) Results: The total of 304 bacterial protein matches were detected based on two or more peptide hits. Significantly regulated microbial proteins like virulence factor type IV secretion system protein CagE from *H. pylori* were found with more abundance in gastritis than in GC or NGM. This finding could reflect the increased microbial involvement in mucosa inflammation in line with current hypotheses. Abundant proteins across species were heat shock proteins and elongation factors. (4) Conclusions: Next to the bulk of human proteins, a number of species-specific bacterial proteins were detected in stomach biopsies of patients with gastroduodenal diseases, some of which, like those expressed by the cag pathogenicity island, may provide gateways to disease prevention without antibacterial intervention in order to reduce antibiotic resistance.

Keywords: gastric cancer; gastritis; ulcer; proteomics; *Helicobacter pylori*

1. Introduction

The American Cancer Society estimates about 26,380 new cases of stomach cancer and about 11,090 related deaths in the US in 2022 [1]. In the early 20th century, gastric cancer (GC) was the leading cause of cancer death in the US, a situation which is continuously improving—the number of new cases has been dropping by ~1.5% each year over the last 10 years [1]. This trend has been associated, besides the reduction in other risk factors [2], with the decline in *Helicobacter pylori* infections [1,3,4]. In other countries, particularly in East Asia, GC is still much more common as a result of insufficient sanitary standards and poor living conditions [3–7]. For instance, the frequency of GC in Pakistan has increased from 6.4% (study published in 2014 [8]) to 9.1% (our main study, see below, published in 2022 [9]).

*H. pylori* has been classified as a class I carcinogen by the International Agency for Research on Cancer [10]. It is the most common bacterial infection worldwide, affecting
more than 50% of the global population, but only 1–3% of infected individuals ever develop GC [11,12]. Many other factors such as host constituents, environmental conditions, and the microbiota of the stomach may influence the development of gastric malignancies [12,13]. The GC microbiome has received increasing attention during the past years (for further reading of the role of non-\(H.\) pylori bacteria in GC development, see [14]). The stomach inactivates ingested microorganisms by exposing them to gastric fluid (containing gastric acid and proteolytic enzymes) and thus functions as a defensive barrier to harmful microbiota [15]. However, in GC patients, the stomach pH is higher and the microbiome, conclusively, changed [13,15,16]. It has been established that \(H.\) pylori infection can lead to achlorhydria and decreased acid secretion, thus directly contributing to alterations in the gastric microbiota (Figure 1) [11,13]. It is however not clear if the new microorganisms favor carcinogenesis or are only a result of the changed microenvironment [13].

![Figure 1. Changes in gastric microbiota and microenvironment during carcinogenesis (adapted from [11,13,16]). Following infection, \(H.\) pylori dominates the gastric microbiota leading to chronic gastritis, reduced acid secretion, and alterations in the gastric microbiome.](image)

The investigation of the GC microbiome is not straightforward and is a cause of much debate (for a recent review of pros and cons, see [13]). Arguments concern both the sample source (mostly biopsies today) and the analysis technique (16s rRNS and whole genome sequencing); the reproducibility of the results is thus limited [13]. Moreover, comparative data from the healthy stomach are hardly available for ethical reasons. Nevertheless, the carcinogenesis cascade shown in Figure 1 is widely accepted, as well as the role of microbial virulence factors (see below) [11–13,15,16].

While many microbial genomics data for gastric diseases are available, their complementation with protein information is still a considerable challenge [17,18]. Most studies such as the region-resolved mucosa proteome of the human stomach focused on human proteins only [19]. Metaproteomics requires the parallel measurement of thousands of proteins from an unknown number of species, namely the host and the cohabiting complex microbiome. This task presents problems on all fronts from sample handling to data mining. For instance, sample preparation methods are known to bias the recovery of host and microbial proteins, respectively [20]. In terms of the analysis of mass spectrometry (MS)-based protein expression data, databases of all organisms present are, in principle, needed, but not for every species yet available. Furthermore, the parallel use of many proteome databases extends the search space dramatically, leading to long calculation times and increased numbers of false-positive assignments, not the least due to homology effects. As a compromise, scientists study simplified microbiomes [21]. Moreover, bioinformatics approaches such as deep learning [22] and iterative searches [18] try to find a way to handle the mass of data, but they are all limited by the spectral quality of the MS raw data and the complexity of the sample.
It is, despite all limitations, of interest to learn about the presence of abundant microbial proteins in biopsies, as they may exert an influence on the tissue environment. We have thus tested MS-based comparative protein expression analysis data of gastric biopsies from patients suffering from gastritis, ulcers, as well as GC in a sub-project of a large study (for results on human proteins, see companion paper [9]). The general aim of the entire project was to generate data, which assist in reducing the number of referrals to endoscopy, which has considerably increased in recent years. This has been achieved based on MS human protein expression results, with the proposal of a lab test of the fibrinogen-to-albumin ratio at the primary to secondary care level, which recognizes gastritis. Our study [9] came with a wealth of meta-data, clinical information, and histopathological evaluation, along with H. pylori infection status (Aziz, S.; König, S.; Umer, M.; Iqbal, S.; Akhter, T. S.; Ahmad, T.; Zahra, R.; Ibrar, M.; Rasheed, F. Risk factor profiles for gastric cancer prediction with respect to Helicobacter pylori: A study of a tertiary care hospital in Pakistan. In submission). We have compared the biopsy and serum protein profiles of 219 patients and elucidated two GC serum marker panels, 29preGC-P (29 proteins significant in early-stage cancer) and 10GC-P (10 proteins significant in advanced cancer) [9].

Here, we set these results in perspective to the data obtained for the bacterial proteins detected in stomach biopsies. In the past, H. pylori was considered the only bacterium which can reside underneath the gastric mucosa and may be involved in gastroduodenal clinical complications and especially GC. H. pylori is known to have various virulence factors including vacuolating cytotoxin A (VacA) and cytotoxin-associated gene pathogenicity island (cagPAI). CagPAI encodes the type 4 secretion system (TSS4) to translocate cytotoxin-associated gene A (cagA) protein in gastric epithelial host cells to initiate carcinogenesis [23]. This concept has now changed with the emerging field of the proteomics of the human microbiome. The human gastrointestinal tract contains trillions of microbes that can live therein by forming a symbiotic relationship with their host; they play a vital role in human health and disease [24]. Bacteroides, Fusobacteria, Actinobacteria, and Firmicutes were, for instance, enhanced in intraepithelial neoplasia and gastric cancer, as detected by 16S rRNA sequencing [25]. This identification of other microbial species in gastric mucosa along with H. pylori has challenged the previous reports. We have selected the species H. pylori, Acinetobacter baumannii, Escherichia coli, Fusobacterium nucleatum, and Bacteroides fragilis because those organisms have been associated with gastrointestinal cancer [12,26–29]. B. fragilis produces toxins to cause colon cancer [30] and F. nucleatum was associated with poor prognosis in patients who were diagnosed with Laurens’s diffuse type GC [27]. A. baumannii is a multidrug-resistant bacterium [31], and E. coli K12 plays a role in the upregulation of programmed cell death ligand-1 (PD-L1) via the NF-κB pathway in the inflamed tissues of the intestine for immune evasion [32]. This is the first investigation, to the best of our knowledge, which provides results on the protein level rather than reporting genes associated with various gastrointestinal diseases.

2. Results and Discussion

2.1. Patients and Samples

Extensive details on patients and samples are available in the companion paper to this project [9]. Briefly, symptomatic patients having upper gastroduodenal problems (acid reflux, abdominal pain, heartburn, vomiting, bloating) attending the Center for Liver and Digestive Diseases, Holy Family Hospital, Rawalpindi, for gastroduodenal endoscopy were enrolled. Biopsies were available from 75 patients and they were divided into groups according to the gastroduodenal clinical manifestations and histopathological evaluation (normal mucosa—NGM (n = 12), mild gastritis—MiG (n = 11), moderate gastritis—MoG (n = 11), marked gastritis—MaG (n = 11), pan gastritis—PanG (n = 5), ulceration—U (gastric ulcer, duodenal ulcer, n = 12), and GC (first and advanced stage, n = 13)). Most of the study participants (70%) were H. pylori positive. Gastric biopsy specimens were, if possible, collected from the normal (N) and adjacent diseased (D) parts of the stomach antrum during gastroduodenal endoscopy.
2.2. General Results

Using the high-definition MS data sets of the tryptically digested proteins from biopsies (for experimental details and the analysis of the human proteins see companion paper [9]), the combined Uniprot protein database of *H. pylori, A. baumannii, E. coli, F. nucleatum*, and *B. fragilis* was searched (Table 1). A total of 304 matches were found requesting a minimum of two peptide hits. The data are given in the Supplement (Table S1: all data; Tables S2–S9: data for *H. pylori*-positive samples, diseased sites; Table S2: GC vs. MaG/MoG; Table S3: GC vs. U; Tables S4–S9: NGM vs.; Table S4—GC, Table S5—MaG, Table S6—MiG, Table S7—MOG, Table S8—PanG, Table S9—U); for an overview of the whole data set, see Table 1 (Please be aware that statistical results depend on the data set studied. Thus, they may differ for the various comparisons shown in the Supplement). As is typical in proteomic analysis, for several hits in the data lists, multiple accession numbers were reported for homologous proteins, despite the fact that at least one unique tryptic peptide had to be detected. Thus, in order to clarify the true contribution of an individual protein, orthogonal analyses have to follow. Here, we discuss the results of this first global analysis.

Table 1. Significantly changed bacterial proteins detected in stomach biopsies in the global analysis of all samples (Anova *p* < 0.02, confidence score > 50, fold change > 2, excluding proteins of no known function). For each MS data set, which was presented to Progenesis software, the cumulated ion intensities were used to calculate fold values for protein matches. The groups showing the highest and the lowest mean values are reported. In the case of multiple assignments of the same protein, only the best match is given. For details see Supplementary Table S1, for binary comparison Tables S2–S9. NGM has been italicized, and GC was marked in bold. Interestingly, the lowest mean condition is populated by NGM, MiG, and GC indicating more involvement of bacterial proteins in gastritis and ulcer.

| Accession | Peptide Count | Unique Peptides | Confidence Score | Max Fold Change | Highest Mean Condition | Lowest Mean Condition | Mass | Description | Name |
|-----------|---------------|-----------------|------------------|-----------------|------------------------|-----------------------|------|-------------|------|
| **H. pylori** |               |                 |                  |                 |                        |                       |      |             |      |
| Q48252    | 32            | 30              | 201              | 3.5             | PanG                   | GC                    | 112,648 | Type IV secretion system protein CagE | cagE |
| P55991    | 30            | 10              | 195              | 2.4             | MaG                    | MiG                   | 84,222 | DNA topoisomerase 1 | topA |
| Q9ZMD2    | 11            | 2               | 84               | 2.3             | PanG                   | GC                    | 71,311 | Chaperone protein HtpG | htpG |
| B2USI5    | 13            | 4               | 77               | 2.8             | MoG                    | GC                    | 67,412 | Elongation factor 4 | kepA |
| Q9ZKE4    | 12            | 3               | 74               | 4.4             | U                      | NGM                   | 71,164 | Primosomal protein N* | priA |
| B5Z96     | 11            | 3               | 64               | 2.7             | PanG                   | NGM                   | 39,970 | Elongation factor Ts | tsf  |
| Q9ZKF6    | 8             | 7               | 52               | 2.3             | MoG                    | MiG                   | 62,699 | 30S ribosomal protein S1 | rpsA |
| **F. nucleatum** |             |                 |                  |                 |                        |                       |      |             |      |
| Q8RGE2    | 46            | 40              | 372              | 2.8             | MaG                    | NGM                   | 50,219 | ATP synthase subunit beta | atpD |
| Q8RFD1    | 18            | 14              | 109              | 3.5             | MaG                    | GC                    | 91,782 | Alpha-1,4 glucan phosphorylase | FN0857 |
| Q8RSZ3    | 13            | 12              | 85               | 2.1             | PanG                   | NGM                   | 11,080 | DNA/RNA helicase (DEAD/DEAH BOX family) | FN1974 |
| Q8RFA3    | 10            | 8               | 75               | 3.1             | PanG                   | NGM                   | 44,947 | Transcriptional regulator_TetR family | FN0813 |
| Q8RHQ8    | 12            | 8               | 75               | 2.9             | PanG                   | GC                    | 97,405 | Chaperone protein ClpB | clpB |
| Q8RF1     | 10            | 8               | 73               | 2.3             | PanG                   | MiG                   | 30,287 | Oligopeptide transport ATP-binding protein oppD | FN1649 |
| Q8R6O4    | 11            | 8               | 60               | 2.1             | PanG                   | MiG                   | 78,086 | Protein translation elongation factor G (EF-G) | FN1546 |
| **E. coli** |               |                 |                  |                 |                        |                       |      |             |      |
| P33341    | 17            | 15              | 99               | 2.9             | MoG                    | GC                    | 92,510 | Outer membrane usher protein YebB | yebB |
| P23909    | 17            | 3               | 99               | 2.7             | PanG                   | NGM                   | 95,569 | DNA mismatch repair protein MutS | mutS |
| P32158    | 13            | 1               | 79               | 2.2             | MaG                    | GC                    | 77,902 | Sulfatoxidase | ybQ |
| A0A6D2W465 | 14          | 13              | 75               | 4.6             | PanG                   | NGM                   | 69,172 | Chaperone protein DnaK | dnaK |
| P14565    | 10            | 9               | 66               | 2.7             | MaG                    | NGM                   | 19,2016 | Multifunctional conjugation protein TraI | traI |
As no enrichment of any kind has been performed, those 304 protein matches represented the most abundant proteins for each species. Chaperones, ribosomal proteins, enzymes, and elongation factors were detected as expected. The concentration of individual proteins in different organisms has been investigated by others with two-dimensional gel electrophoresis and $^{14}$C labeling, MS, and fluorescent light microscopy, which showed that especially these proteins are highly abundant [33]. For instance, the elongation factor EF-Tu, responsible for mediating the entrance of tRNA to the free site of the ribosome, was characterized as the most abundant protein with a copy number of $\approx 60,000$ proteins per bacterial genome [33]. Newer work demonstrated in E. coli cytosol that highly concentrated proteins were involved in protein synthesis, energy metabolism, and binding, while proteins associated with transcription, transport, and cellular organization were relatively rare (dynamic range of $\sim 10^5$) [34]. We noted that some proteins such as elongation factors 4 (EF4, lepA), TS (EF-TS, tsf), and Tu (EF-Tu, tuf) were found for several of the bacterial species and wondered about false-positive assignment due to homologous peptides or limited spectral information. Blast analysis in the Uniprot database revealed 76.8% homology of H. pylori EF4 to that of Wolinella succinogenes; the homology for the species we considered was in the range of 50–60%. EF4 of B. fragilis was 88.5% homologous to that of Paraprevotella clara. Prevotella are among the enriched genera proteobacteria in GC [11]. Thus, our data, and metaproteomics data generally, should be used with care; the true presence of a particular protein of a specific species always needs to be proven and validated by other analytical methods [35]. Therefore, we further analyze our results in a conservative manner considering only proteins assigned with a confidence score better than 50. Below, we discuss the hits, which were of special importance for each bacterial species, based on the global analysis containing all data sets (Table 1). Specific data for binary comparisons of individual sample sets may slightly differ from the global analysis and are available in the Supplement.

### Table 1. Cont.

| Accession   | Peptide Count | Unique Peptides | Confidence Score | Max Fold Change | Highest Mean Condition | Lowest Mean Condition | Mass       | Description                                                                                      | Name          |
|-------------|---------------|-----------------|------------------|-----------------|------------------------|-----------------------|------------|--------------------------------------------------------------------------------------------------|---------------|
| A0A6D2XSN2  | 12            | 9               | 65               | 2.1             | U                      | MiG                   | 36,025     | Rpn family recombination-promoting nuclease/putative transposase                               | FAZ83_12895   |
| A0A4SB3J9   | 11            | 10              | 62               | 5.0             | MoG                    | GC                    | 42,787     | Lipid-A-disaccharide synthase                                                                | lpxB          |
| A0A6D2XJ30  | 8             | 7               | 58               | 2.5             | PanG                   | MiG                   | 12,295     | 50S ribosomal protein L7/L12                                                                | rplL          |
| A0A380YYU9  | 77            | 69              | 452              | 2.5             | MaG                    | GC                    | 55,261     | ATP synthase subunit beta                                                                | atpD          |
| Q5LE2       | 31            | 29              | 182              | 3.8             | MaG                    | GC                    | 99,598     | Beta-mannosidase                                                                            | bmnA          |
| A0A380YS6   | 27            | 25              | 166              | 3.0             | PanG                   | GC                    | 148,490    | Putative cobalamin biosynthesis-related membrane protein                                      | cobN_1        |
| Q5LEB7      | 23            | 20              | 143              | 2.6             | MiG                    | GC                    | 107,262    | Type I restriction enzyme R Protein                                                          | hsdR          |
| Q5L9C7      | 19            | 16              | 113              | 2.1             | PanG                   | GC                    | 106,621    | 4-alpha-glucanotransferase                                                                  | malQ          |
| Q5L9N9      | 10            | 7               | 57               | 3.6             | MoG                    | NGM                   | 73,150     | ParB-like partition proteins                                                              | parB_1        |
| A0A380YS49  | 11            | 9               | 56               | 3.5             | PanG                   | GC                    | 43,808     | Elongation factor Tu                                                                            | tuf           |
| Q5L7x1      | 8             | 6               | 50               | 2.5             | MoG                    | NGM                   | 69,190     | Metal-dependent hydrolase                                                                  | BP9343_4047   |
| A. baumannii |               |                 |                  |                 |                        |                       |            |                                                                                               |               |
| A0A009HW70  | 29            | 25              | 152              | 4.1             | ParG                   | MiG                   | 144,320    | Tape measure domain protein                                                                | J512_0646     |
| A0A009HB7   | 20            | 16              | 121              | 2.0             | ParG                   | NGM                   | 127,978    | Phage integrase family protein                                                              | J512_2803     |
| A0A009UU53  | 16            | 9               | 88               | 2.4             | ParG                   | NGM                   | 97,429     | Translation initiation factor IF-2                                                          | iniB          |
| A0A009QLQ7  | 12            | 10              | 66               | 2.9             | ParG                   | GC                    | 123,032    | DEAD/DEAH box helicase family protein                                                      | J512_2067     |
| A0A009XJ4A1 | 12            | 8               | 61               | 3.1             | U                      | NGM                   | 102,148    | Pyruvate dehydrogenase E1 component                                                      | aceE          |
| A0A009FT43  | 7             | 6               | 50               | 3.9             | U                      | MiG                   | 27,161     | Short chain dehydrogenase family protein                                                  | J512_0848     |
2.3. H. pylori

*H. pylori* uses chemotaxis to avoid areas of low pH and also neutralizes the acid in the stomach environment by producing large amounts of urease, which breaks down urea to carbon dioxide and ammonia [36]. The latter is toxic to epithelial cells as are biochemicals produced by *H. pylori* such as proteases, VacA [37], and some phospholipases [36]. CagA can also cause inflammation and is a potential carcinogen [38,39]. It is absent in asymptomatic human carriers [40]. TSS4 expressed by cagPAI delivers CagA and inflammation-inducing peptidoglycan to the stomach epithelial cells, starting the inflammation cascade [41]. We detected TSS4 protein CagE, but not CagA and VacA, which was possibly a matter of concentration. The *cagE* gene has been published as a biomarker for erosive gastritis [42] and as a virulence factor associated with duodenal ulceration in children [43]. On the genomic level, *cagE* was named as a prognostic marker for intestinal and diffuse gastric cancer [44]. We found its highest abundance in PanG (3.5-fold more than the overall lowest concentration found in GC, Table 1); in U vs. NGM, its concentration was not very different (fold 1.9, Supplementary Table S9). Thus, on the protein level, CagE does not appear to be a GC marker in tissue biopsies.

Primosomal protein N’ was present more than 4-fold in U vs. NMG (overall highest mean fold value, Table 1); 2.5-fold in GC vs. NMG (Supplementary Table S4). It is a member of the replication restart primosome, which is essential for bacterial survival [45]. All other proteins changed only between two- and three-fold, including DNA topoisomerase I, a protein that is crucial in maintaining DNA superhelicity, thereby regulating various cellular processes [46]. The chaperone protein HtpG was fairly balanced in all biopsies; at the maximum, it was slightly more abundant in PanG vs. GC biopsies (2.3-fold). Interestingly, the transcription of the monocistronic *hptG* gene was switched off after heat shock [47]. Successful pathogens have developed robust chaperone systems to conquer the stressful host response to infection so that increasingly the potential of exploiting pathogen chaperones as drug targets is discussed [48].

As noted above, EF4 and EF-TS were also abundant, but more so in gastritis than GC. While both proteins are involved in protein synthesis [49,50], EF4 also promotes cell death under lethal stress [51]. EF-Tu, which was suggested as a potential adherence factor of *H. pylori* during pathogenesis [52,53], was detected here at 6.3-fold more abundance in mild gastritis than in GC. Other proteins have been found in the biopsies, but with no great change between sample types (fold change < 2) such as copper-transporting ATPase. *H. pylori*-associated gastritis is accompanied by a deficiency of copper in gastric epithelial and endothelial cells [54].

2.4. F. nucleatum

*F. nucleatum* is an oral bacterium commensal to the human oral cavity that plays a role in periodontal plaque [55]. It is also known that *F. nucleatum* creates a pro-inflammatory environment, which is conducive to tumor growth in colon cancer [56]. We detected α1-4 glucan phosphorylase, which was seen 3.5-fold more in MaG than in GC (Table 1). This enzyme has been mainly studied in *E. coli*; roles in the regulation of endogenous glycogen metabolism in periods of starvation, stress response, or adaptation were suggested [57]. The TetR family transcriptional regulator (3.1-fold PanG > NGM) is associated with antibiotic resistance, but also with roles in metabolism and quorum sensing [58]. The majority of the detected proteins exhibited fold changes < 3 including EF-G, chaperone protein ClpB, and ATP synthase β. DNA/RNA helicase (DEAD/DEAH BOX family) belongs to the superfamily 2 RNA helicase proteins, which chaperone folding and promote rearrangements of structured RNAs [59], it appeared fairly balanced across the biopsies of this project (2.1-fold).

2.5. E. coli

*E. coli* and other facultative anaerobes constitute about 0.1% of gut microbiota [60]. Most *E. coli* strains are harmless, but some serotypes can cause serious food poisoning
in their hosts. The harmless strains are part of the normal microbiota of the gut and can benefit their hosts by producing vitamin K$_2$ and preventing the colonization of the intestine with pathogenic bacteria [61,62]. More than a hundred complete genomic sequences of *Escherichia* are known and they show a remarkable amount of diversity; around 80% of each genome can vary among isolates [63]. Each individual genome contains between 4000 and 5500 genes (38% identified experimentally [64]), but the total number of different genes among all of the sequenced *E. coli* strains (the pangenome) exceeds 16,000. It has been assumed that two-thirds of the *E. coli* pangenome originated in other species and arrived through the process of horizontal gene transfer [65]. The transfer of DNA from one bacterial cell to another through the intervening medium appears to be part of an adaptation to stressful conditions, including those that cause DNA damage [66]. We detected DNA mismatch repair protein MutS [67] and Rpn family recombination-promoting nuclease/putative transposase [68], which are involved in these functions.

Besides the chaperone DnaK (maximum fold change 4.6, PanG vs. NGM), lipid-A-disaccharide synthase, which is a virulence factor in pathogenic bacteria [59], exhibited considerable differences across the biopsies; it was five-fold more abundant in MoG than in GC. All other proteins only changed less than three-fold and they were upregulated in MaG and U. The outer membrane usher protein YehB is part of the chaperone/usher pathway, which assembles adhesive and virulence-associated pili [69]. Multifunctional conjugation protein TraI has a role in antibiotic resistance propagation [70]. Sulfoquinovosidase is the gateway enzyme to sulfoglycolytic pathways [71].

2.6. *B. fragilis*

*B. fragilis* is part of the normal microbiota of the human colon and is generally commensal [72]. It is essential for healthy gastrointestinal functions such as mucosal immunity and host nutrition [73]. *B. fragilis* is an aerotolerant, anaerobic chemoorganotroph capable of degrading a wide variety of glycans, biopolymers, polysaccharides, and glycoproteins. It produces fatty acid as a byproduct of carbohydrate fermentation which can then be used as energy by the host; it was shown that animals lacking gut bacteria require 30% more caloric intake to maintain body mass [74]. The *B. fragilis* group is the most commonly isolated Bacteroidaceae in anaerobic infections, and *Bacteroides* are characterized by the highest resistance rates amongst anaerobic bacteria [75]. In biopsies, major changes were indicated for ParB-like partition protein (5.6-fold MoG > NGM). In bacteria, partition systems contribute to the faithful segregation of both chromosomes and low-copy-number plasmids [76]. Besides EF-Tu (3.5-fold PanG > GC), β-mannosidase was higher regulated than 3-fold (3.8-fold MaG > GC). It plays an important role in the polysaccharide degradation pathway [77]. Other proteins specifically seen in this organism were a putative cobalamin biosynthesis-related membrane protein [78], type I restriction enzyme R protein [79], 4-α-glucanotransferase, and metal-dependent hydrolase [80].

2.7. *A. baumannii*

*A. baumannii* can be an opportunistic pathogen in humans, affecting people with compromised immune systems, and is becoming increasingly important as a hospital-derived infection [81]. *A. baumannii* has also been identified as an ESKAPE pathogen, a group of pathogens with a high rate of antibiotic resistance that are responsible for the majority of nosocomial infections [82]. It can survive on artificial surfaces for an extended period of time, likely due to its ability to form biofilms [83]. In our experiments, regulated more than four-fold (PanG vs. MiG) was a tape measure domain protein, which received this name because the length of the corresponding gene is proportional to the length of the tail of a bacteria-infecting phage [84]. In fact, as the nosocomial pathogen *A. baumannii* is multidrug-resistant, phage therapy as an alternative to antibiotic therapy has been recovered [85]. Interestingly, there was also a phage integrase family protein detected predominantly in PanG biopsy samples (two-fold >NGM), a protein group which has risen to prominence as genetic tools [86]. Translation initiation factor IF-2 (2.4-fold PanG >
NGM) synthesis was shown to be induced following cold stress, while ribosome synthesis and assembly slowed down [87]. Upregulated in U was a short-chain dehydrogenase family protein (3.9-fold vs. MiG). Its structure has been described from a genomic island of a clinical strain of A. baumannii [88]. Additionally, abundant in U was the pyruvate dehydrogenase E1 component (3.1-fold > NGM). It is part of the pyruvate dehydrogenase complex enzymatic system that is crucial in cellular metabolism as it controls the entry of carbon into the Krebs cycle [89].

2.8. Limitations

As discussed already in part above, this study suffers from limitations. We have been fortunate in having available to us samples of different gastrointestinal diseases for this project, but for some subgroups such as PanG, only a few biopsies were available, reducing the power of the analysis. The results should thus be considered with care in their context. Moreover, while the proteomic analysis of total proteomes has great value in providing an overview of the sample composition, it is a general and, in a way, a superficial experiment, which is not always able to properly identify homologous proteins or isoforms. This was discussed for elongation factors in Section 2.2. Subsequent orthogonal analyses need to be employed to pinpoint the presence of proteins of interest. Furthermore, proteomic experimental results are big data sets containing tens of thousands of peptide signals. Their analysis requires software support, which can generate false-positive matches depending on the search and filter criteria chosen. The best way to exclude these is still the manual control of individual mass spectra, which is not feasible for large data sets [35]. We have thus used both the number of detected peptides and the confidence score to eliminate false hits as much as possible.

3. Conclusions

No such comprehensive proteomics research study has been conducted before, which comprised various gastroduodenal afflictions with respect to H. pylori infection. This is also the first investigation to the best of our knowledge, which has provided results on the protein level rather than reporting regulated genes. In the past, H. pylori was considered the only bacterium living beneath the gastric mucosa and which may be involved in gastric cancer initiation. We have here detected proteins of four other bacterial pathogens, A. baumannii, E. coli, F. nucleatum, and B. fragilis, in biopsy specimens of gastric diseased patients. Our measurements did not paint a comprehensive picture of the microbial proteins; they rather gave a first impression as we focused on the most confident protein matches. Ambiguity remained with regard to isoforms and homologous proteins, and individual hits will need to be validated. Abundant bacterial proteins were assigned, such as elongation and heat shock factors, which seemed to be highly concentrated across species. Other proteins, such as the H. pylori virulence factor CagE [42,43], appeared to be specific. For the oral bacterium E. nucleatum, we detected α1-4 glucan phosphorylase, which is involved in the regulation of endogenous glycogen metabolism during stress [57]. In E. coli, the virulence factor lipid-A-disaccharide synthase [59] was found especially in gastritis. So was β-mannosidase in the commensal bacterium B. fragilis; the enzyme is important in the polysaccharide degradation pathway [77]. In the opportunistic pathogen A. baumannii, the pyruvate dehydrogenase E1 component was regulated, which is crucial in cellular metabolism [89]. Interestingly, bacterial proteins of interest (Table 1) were more abundant in advanced gastritis than in NGM and GC. This finding could be reflective of increased microbial involvement in mucosa inflammation in line with current hypotheses [90]. For the H. pylori virulence factor CagE, evidence to that effect already exists [42,43].

The eradication of H. pylori has been considered as a measure to prevent GC [82,83] because it was recognized as a major risk factor. Antibiotic treatment obviously affects microbiota in general, however, leading to the temporary dysregulation of the microbiome and supporting antibacterial resistance. Thus, such harsh treatment needs to be applied with care and more selective; personalized approaches are called for (for more information...
on the exploitation of microbiota in personalized medicine, see [91]). Clearly, in disease research, the entire microbiome in its complexity is of importance. The findings of this study are helpful in redirecting the research focus on bacterial pathogens other than \textit{H. pylori} residing underneath the gastric mucosa at acidic pH. The lack of diagnosis of these pathogens may be involved in the increase in antimicrobial resistance when treating \textit{H. pylori} infection. It may thus be necessary to test for more bacterial species in routine lab work.

Moreover, information on the presence and regulation of various proteins of bacterial pathogens assists the scientific community in its investigation of microbial species in the context of gastric disease treatment and prevention such as the design of novel inhibitors to halt the spread of bacterial infections and GC. More research is still needed on the molecular pathways and host–pathogen interactions in gastric disease progression.

4. Materials and Methods

4.1. Permissions

Ethical approvals were obtained from the Ethical Technical Committee of the Pakistan Institute of Nuclear Science and Technology (PINSTECH), Islamabad (Ref.-No. PINST/DC-26/2017), the Bioethics Committee of Quaid-i-Azam University, Islamabad (Ref.-No. BBC-FBS-QUAU2019-159), the Institutional Research Forum of Rawalpindi Medical University, Rawalpindi (Ref.-No. R-40/RMU), and the Ethics Committee of the University of Münster, Germany (Ref.-No. 2021-339-f-N). Informed written consent was obtained from each participant.

4.2. Protein Expression Analysis

Sample preparation and measurement were described in reference [9]. Briefly, proteins were extracted from the biopsies, trypically digested, and subjected to reversed-phase liquid chromatography coupled to high-definition MS with Synapt G2 Si/M-Class nanoUPLC (Waters Corp., Manchester, UK). Label-free data-independent quantification experiments were analyzed with Progenesis for Proteomics (QIP, Nonlinear Diagnostics/Waters Corp.) using the combined Uniprot databases for from \textit{H. pylori}, \textit{A. baumannii}, \textit{E. coli K12}, \textit{F. nucleatum} and \textit{B. fragilis} (download 8/25/2021). At least two peptides were required for protein assignment. Fold values as well as ANOVA \( p \)-values and confidence levels were also determined using Progenesis.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27175410/s1, Additional analysis data (for details see 2.2.), Excel-File: Supplement.

Author Contributions: Conceptualization, F.R. and S.A.; Methodology, S.A.; Formal Analysis, S.A. and S.K.; Writing—Original Draft Preparation, S.A. and S.K.; Writing—Review and Editing, S.A., S.K., and F.R.; Supervision, R.Z. and F.R.; Project Administration, S.A.; Funding Acquisition, S.A.; Endoscopic evaluation and sampling, T.S.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research study was financially supported by the Pakistan Science Foundation (project # PSF/res/C-PINSTECH/Med (497)). SA was supported by a fellowship from the International Research Support Initiative Program, Higher Education Commission, Pakistan. (No: 1-S/HEC/HRD/2020/10636, PIN: IRSIP 45 BMS 101).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Bioethics Committee of Quaid-i-Azam University, Islamabad (Ref.-No. BBC-FBS-QUAU2019-159), the Ethical Technical Committee, Pakistan Institute of Nuclear Science and Technology (PINSTECH), Islamabad, Pakistan (Ref.-No. PINST/DC-26/2017), the Institutional Research Forum, Holy Family Hospital, Rawalpindi Medical University, Rawalpindi (Ref.-No. R-40/RMU), and Ethics Committee of the University of Münster, Germany (Ref.-No. 2021-339-f-N).

Informed Consent Statement: Informed written consent was obtained from all subjects involved in the study.
Data Availability Statement: All data are available in the Supplementary Materials.

Acknowledgments: We acknowledge technical assistance from Doreen Ackermann (IZKF).

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations
GC—gastric cancer, MiG—mild gastritis, MiGa—typical MiG, MiGn—normal MiG, MoG—moderate gastritis, MaG—marked gastritis, PanG—pan gastritis, NGM—normal gastric mucosa, HPn—H. pylori positive, HPn—H. pylori negative, D—disease site, N—normal site, MS—mass spectrometry.

References
1. American Cancer Society. Available online: www.cancer.org/cancer/stomach-cancer/about/key-statistics.html (accessed on 15 March 2022).
2. Poorolajal, J.; Moradi, L.; Mohammadi, Y.; Cheraghi, Z.; Gohari-Ensaf, F. Risk factors for stomach cancer: A systematic review and meta-analysis. Epidemiol. Health 2020, 42, e2020004. [CrossRef] [PubMed]
3. Sitzar, R.; Skierucha, M.; Mielko, J.; Offerhaus, G.J.A.; Maciejewski, W.; Polkowski, W.P. Gastric cancer: Epidemiology, prevention, classification, and treatment. Cancer Manag. Res. 2018, 10, 239–248. [CrossRef] [PubMed]
4. Ferley, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2014, 136, E359–E386. [CrossRef] [PubMed]
5. Monno, R.; De Laurentis, V.; Trerotoli, P.; Roselli, A.M.; Ierardi, E.; Portincase, P. Helicobacter pylori infection: Association with dietary habits and socioeconomic conditions. Clin. Res. Hepatol. Gastroenterol. 2019, 43, 603–607. [CrossRef]
6. Youn Nam, S.; Park, B.J.; Nam, J.H.; Ryu, K.H.; Kook, M.C.; Kim, J.; Lee, W.K. Association of current Helicobacter pylori infection and metabolic factors with gastric cancer in 35,519 subjects: A cross-sectional study. United Eur. Gastroenterol. J. 2019, 7, 287–296. [CrossRef]
7. Bernardo Guevara, B.; Cogdill, A.G. Helicobacter pylori: A review of current diagnostic and management strategies. Dig. Dis. Sci. 2020, 65, 1917–1931. [CrossRef]
8. Rasheed, F.; Campbell, B.J.; Alfizah, H.; Varro, A.; Zahra, R.; Yamaoka, Y.; Pritchard, D.M. Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. Helicobacter 2014, 19, 387–399. [CrossRef]
9. Aziz, S.; Rasheed, F.; Zahra, R.; König, S. Gastric cancer pre-stage detection and early diagnosis of gastritis using serum protein signatures. Molecules 2022, 27, 2857. [CrossRef]
10. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; IARC: Lyon, France, 1994; Volume 61, pp. 1–241.
11. Noto, J.M.; Peek, R.M., Jr. The gastric microbiome, its interaction with Helicobacter pylori, and its potential role in the progression to stomach cancer. PLoS Pathog. 2017, 13, 1006573. [CrossRef]
12. Muzahed. Helicobacter pylori oncogenicity: Mechanism, prevention, and risk factors. Sci. World J. 2020, 2020, 3018326.
13. Barra, W.F.; Sarquis, D.P.; Khayat, A.S.; Khayat, B.C.M.; Demachi, S.; Anaissi, A.K.M.; Ishak, G.; Santos, N.P.C.; dos Santos, S.E.B.; Burbano, R.R.; et al. Gastric cancer microbiome. Pathobiology 2021, 88, 156–169. [CrossRef] [PubMed]
14. Li, Q.; Yu, H. The role of non-H. pylori bacteria in the development of gastric cancer. Am. J. Cancer Res. 2020, 10, 2271–2281. [PubMed]
15. Yang, L.; Nell, S.; Suerbaum, S. Survival in hostile territory: The microbiota of the stomach. FEMS Microbiol. Rev. 2013, 37, 736–761. [CrossRef] [PubMed]
16. Correa, P.; Piazuelo, M.B. The gastric precancerous cascade. J. Dig. Dis. 2012, 13, 2–9. [CrossRef] [PubMed]
17. Blackburn, J.M.; Martens, L. The challenge of metaproteomic analysis in human samples. Exp. Rev. Proteom. 2016, 13, 135–138. [CrossRef]
18. Bassignani, A.; Plancaede, S.; Berland, M.; Blein-Nicolas, M.; Guillot, A.; Chevret, D.; Moritz, C.; Huet, S.; Rizkalla, S.; Clément, K.; et al. Benefits of iterative searches of large databases to interpret large human gut metaproteomic data sets. J. Proteome Res. 2021, 20, 1522–1534. [CrossRef]
19. Ni, X.; Tan, Z.; Ding, C.; Zhang, C.; Song, L.; Yang, S.; Liu, M.; Jia, R.; Zhao, C.; Song, L.; et al. A region-resolved mucosa proteome of the human stomach. Nat. Commun. 2019, 10, 39. [CrossRef] [PubMed]
20. Gavin, P.G.; Wong, J.; Loo, D.; Zipris, D.; Hill, M.M.; Hamilton-Williams, E.E. Metaproteomic sample preparation methods bias the recovery of host and microbial proteins according to tax and cellular compartment. J. Proteom. 2021, 240, 104219. [CrossRef]
21. Petruschke, H.; Schori, C.; Canzler, S.; Riesbeck, S.; Poeblein, A.; Daniel, R.; Frei, D.; Segessemann, T.; Zimmermann, J.; Marinos, G.; et al. Discovery of novel community-relevant small proteins in a simplified human intestinal microbiome. Microbiome 2021, 9, 55. [CrossRef]
22. Feng, S.; Sterzenbach, R.; Guo, X. Deep learning for peptide identification from metaproteomics datasets. J. Proteom. 2021, 247, 104316. [CrossRef]
23. Alipour, M. Molecular mechanism of Helicobacter pylori-induced gastric cancer. J. Gastrointest. Cancer 2021, 52, 23–30. [CrossRef] [PubMed]

24. Chen, C.C.; Liou, J.M.; Lee, Y.C.; Hong, T.C.; El-Omar, E.M.; Wu, M.S. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes 2021, 13, 190459. [CrossRef] [PubMed]

25. Wang, R.; Chen, X.Z. Prevalence of atrophic gastritis in southwest China and predictive strength of serum gastrin-17: A cross-sectional study (SiGES). Sci. Rep. 2020, 10, 4523. [CrossRef] [PubMed]

26. Tetz, G.; Tetz, V. Draft genome sequence of Acinetobacter sp. Strain VT-511 isolated from the stomach of a patient with gastric cancer. Prokaryotes 2015, 3, e01202-15. [CrossRef]

27. Boehm, E.T.; Thon, C.; Kupcinskas, J.; Steponaitiene, R.; Skieceviciene, J.; Canbay, A.; Malfertheiner, P.; Link, A. Fusobacterium nucleatum is associated with worse prognosis in Lauren’s diffuse type gastric cancer patients. Sci. Rep. 2020, 10, 16240. [CrossRef]

28. Shariati, A.; Razavi, S.; Ghaznavi-Rad, E.; Jahanbin, B.; Akbari, A.; Norzaee, S.; Darban-Sarokhalil, D. Association between colorectal cancer and Fusobacterium nucleatum and Bacteroides fragilis bacteria in Iranian patients: A preliminary study. Infect. Agent Cancer 2021, 16, 41. [CrossRef]

29. Wang, L.; Zhou, J.; Xin, Y.; Geng, C.; Tian, Z.; Yu, X.; Dong, Q. Bacterial overgrowth and diversification of microbiota in gastric cancer. Eur. J. Gastroenterol. Hepatol. 2016, 28, 261–266. [CrossRef]

30. Cheng, W.T.; Kantilal, H.K.; Davamani, F. The mechanism of Bacteroides fragilis toxin contributes to colon cancer formation. Malays. J. Med. Sci. MJMS 2020, 27, 9. [CrossRef]

31. Kurihara, M.N.; Sales, R.O.; Silva, K.E.; Maciel, W.G.; Simionatto, S. Multidrug-resistant Acinetobacter baumannii outbreaks: A global problem in healthcare settings. Rev. Da Soc. Bras. De Med. Trop. 2020, 53, e20200248. [CrossRef]

32. Lee, S.A.; Wang, Y.; Liu, F.; Riordan, S.M.; Liu, L.; Zhang, L. Diversity and global variations in gastric cancer. Infect. Genet. Evol. 2015, 42, 9. [CrossRef]

33. Alipour, M. Molecular mechanism of Helicobacter pylori-induced gastric cancer. J. Gastrointest. Cancer 2021, 52, 23–30. [CrossRef] [PubMed]

34. Eckburg, P.B.; Bik, E.M.; Bernstein, C.N.; Purdom, E.; Dethlefsen, L.; Sargent, M.; Gill, S.R.; Nelson, K.E.; Relman, D.A. Diversity of the human intestinal microbial flora. Proc. Natl. Acad. Sci. USA 2005, 102, 12,541–12,548. [CrossRef] [PubMed]

35. Ishihama, Y.; Schmidt, T.; Rappsilber, J.; Mann, M.; Hartl, F.U.; Kerner, M.J.; Frishman, D. Protein abundance profiling of the cytosol. BMC Genom. 2008, 9, 102. [CrossRef] [PubMed]

36. Homuth, G.; Domm, S.; Kleiner, D.; Schumann, W. Transcriptional analysis of major heat shock genes of Salmonella typhimurium and Escherichia coli. Infect. Genet. Evol. 2010, 8, 1370–1375. [CrossRef] [PubMed]

37. Waller, E.; Håkanson, R. Acinetobacter baumannii: A brief tutorial on the analysis of peptide fragmentation data for mass spectrometry laymen. BMC Genom. 2007, 8, 146. [CrossRef] [PubMed]

38. Neckers, L.; Tatu, U. Molecular chaperones in pathogen virulence: Emerging new targets for therapy. Cell Host Microbe 2008, 4, 519–527. [CrossRef] [PubMed]
49. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

50. Pech, M.; Karim, Z.; Yamamoto, H.; Nierhaus, K.H. Elongation factor 4 (EF4/LepA) accelerates protein synthesis at increased Mg2+ concentrations. *Proc. Natl. Acad. Sci. USA* 2011, 108, 1012994108. [CrossRef]

51. Li, L.; Hong, Y.; Luan, G.; Mosel, M.; Malk, M.; Drlica, K.; Zhao, X. Ribosomal elongation factor 4 promotes cell death associated with lethal stress. *mBio* 2014, 5, e01708–14. [CrossRef]

52. Chiu, K.-H.; Wexler, H.M. The Genus Bacteroides. In *Microbial Pathogenesis*; E.F., Lory, S., Stackebrandt, E., Eds.; Springer: Berlin/Heidelberg, Germany, 2014; pp. 459–484. [CrossRef]

53. Schinzel, R.; Nidetzky, B. Bacterial *β*-glucan phosphorylases. *Curr. Biol.* 2013, 23, R17–R20. [CrossRef] [PubMed]

54. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

55. Kuwahara, T.; Yamashita, A.; Hirakawa, H.; Nakaya, H.; Kuhara, S.; Hattori, M.; Hayashi, T.; Ohnishi, Y. Genomic analysis of *Bacteroides fragilis* genes *hpcopA* and *hpcopP* constitute a copy operon involved in copper export. *FEMS Microbiol. Lett.* 1996, 145, 181–188. [CrossRef]

56. Wexler, H.M. The Genus Bacteroides. In *The Prokaryotes: Other Major Lineages of Bacteria and the Archaea*; Rosenberg, E., DeLong, E.F., Lory, S., Stackebrandt, E., Eds.; Springer: Berlin/Heidelberg, Germany, 2014; pp. 459–484. [CrossRef]

57. Schinzel, R.; Nidetzky, B. Bacterial *α*-glucan phosphorylases. *FEMS Microbiol. Lett.* 1999, 171, 73–79. [CrossRef]

58. Cuthbertson, L.; Nodwell, J.R. The TetR family of regulators. *Cell Host Microbe* 2007, 12, 288–297. [CrossRef] [PubMed]

59. Bohl, H.O.; Shi, K.; Lee, J.K.; Aihara, H. Crystal structure of lipid A disaccharide synthase LPXB from *Escherichia coli*. *Nat. Commun.* 2018, 9, 377. [CrossRef]

60. Reid, G.; Howard, J.; Ban, B.S. Can bacterial interference prevent infection? *Trends Microbiol.* 2001, 9, 424–428. [CrossRef]

61. Lukjancenko, O.; Wassenaar, T.M.; Ussery, D.W. Comparison of 61 sequenced *Escherichia coli* genomes. *Trends Microbiol.* 2010, 18, 288–290. [CrossRef] [PubMed]

62. Zhaxybayeva, O.; Doolittle, W.F. Lateral gene transfer. *Curr. Biol.* 2011, 21, R242–R246. [CrossRef]

63. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

64. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

65. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

66. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

67. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

68. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

69. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

70. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

71. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

72. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef] [PubMed]

73. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

74. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

75. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

76. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]

77. Burnett, B.J.; Altman, R.B.; Ferrao, R.; Alejo, J.L.; Kaur, N.; Kanji, J.; Blanchard, S.C. Elongation factor Ts directly facilitates the formation and disassembly of the *Escherichia coli* elongation factor Tu-GTP-aminonucleotidyl-tRNA ternary complex. *J. Biol. Chem.* 2013, 288, 13917–13928. [CrossRef]
79. Murray, N.E. Type I restriction systems: Sophisticated molecular machines. Microbiol. Mol. Biol. Rev. 2000, 64, 412–434. [CrossRef] [PubMed]

80. Imamura, H.; Fushinobu, S.; Yamamoto, M.; Kumasaka, T.; Jeon, B.-S.; Wakagi, T.; Matsuzawa, H. Crystal structures of 4-α-glucanotransferase from Thermococcus litoralis and its complex with an inhibitor. J. Biol. Chem. 2003, 278, 19378–19386. [CrossRef]

81. Espinal, P.; Marti, S.; Vila, J. Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces. J. Hosp. Infect. 2012, 80, 56–60. [CrossRef]

82. Uno, Y. Prevention of gastric cancer by Helicobacter pylori eradication: A review from Japan. Cancer Med. 2019, 8, 3992–4000. [CrossRef]

83. Shi, X.; Zhang, J.; Mo, L.; Shi, J.; Qin, M.; Huang, X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine 2019, 98, e15180. [CrossRef]

84. Belcaid, M.; Bergeron, A.; Poisson, G. The evolution of the tape measure protein: Units, duplications and losses. BMC Bioinform. 2011, 12, S10. [CrossRef]

85. Blasco, L.; Bleriot, I.; González de Aledo, M.; Fernández-García, L.; Pacios, O.; Oliveira, H.; López, M.; Ortiz-Cartagena, C.; Fernández-Cuenca, F.; Pascual, A.; et al. Development of an anti-Acinetobacter baumannii biofilm phage cocktail: Genomic adaptation to the host. Antimicrob. Agents Chemother. 2022, 66, e01923-21. [CrossRef]

86. Fogg, P.C.M.; Colloms, S.; Rosser, S.; Stark, M.; Smith, M.C.M. New applications for phage integrases. J. Mol. Biol. 2014, 426, 2703–2716. [CrossRef] [PubMed]

87. Brandi, A.; Piersimoni, L.; Feto, N.A.; Spurio, R.; Alik, J.-H.; Schmidt, F.; Gualerzi, C.O. Translation initiation factor IF2 contributes to ribosome assembly and maturation during cold adaptation. Nucl. Acids Res. 2019, 47, 4652–4662. [CrossRef] [PubMed]

88. Shah, B.; Tetu, S.G.; Harrop, S.J.; Paulsen, I.T.; Mabbutt, B.C. Structure of a short-chain dehydrogenase/reductase (SDR) within a genomic island from a clinical strain of Acinetobacter baumannii. Acta Cryst. 2014, F70, 1218–1323.

89. Sgrignani, J.; Chen, J.J.; Alimonti, A.; Cavalli, A. How phosphorylation influences E1 subunit pyruvate dehydrogenase: A computational study. Sci. Rep. 2018, 8, 14683. [CrossRef] [PubMed]

90. Zeng, M.; Inohara, N.; Nuñez, G. Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal Immunol. 2017, 10, 18–26. [CrossRef] [PubMed]

91. Behrouzi, A.; Nafari, A.H.; Siadat, S.D. The significance of microbiome in personalized medicine. Clin. Transl. Med. 2019, 8, 16. [CrossRef] [PubMed]